• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤标志物透明质酸和透明质酸酶(HYAL1)在头颈部肿瘤中的表达。

Expression of tumor markers hyaluronic acid and hyaluronidase (HYAL1) in head and neck tumors.

作者信息

Franzmann Elizabeth J, Schroeder Grethchen L, Goodwin William Jarrard, Weed Donald T, Fisher Penelope, Lokeshwar Vinata B

机构信息

Department of Otolaryngology, University of Miami School of Medicine, Miami, FL 33101, USA.

出版信息

Int J Cancer. 2003 Sep 1;106(3):438-45. doi: 10.1002/ijc.11252.

DOI:10.1002/ijc.11252
PMID:12845686
Abstract

Characteristic behaviors of head and neck squamous cell carcinoma (HNSCC) include a propensity to occur as multiple synchronous and metachronous tumors, frequent recurrence and metastasis. Early detection of HNSCC and monitoring its recurrence are necessary to improve prognosis. Hyaluronic acid (HA), a component of extracellular matrix, promotes metastasis. Small fragments of HA stimulate angiogenesis. HA fragments are generated when hyaluronidase (HAase), an endoglycosidase, degrades the HA polymer. Using the HA test (an ELISA-like assay) we found that saliva HA levels are 4.9-fold elevated in 11 HNSCC patients (2841 +/- 887 ng/mg protein) when compared to 6 normal controls (579.3 +/- 122.6 ng/mg protein; p = 0.00238). HNSCC patients included in our study were patients with cancers of the oral cavity (n = 4), pharynx (n = 7) and larynx (n = 1). The HA levels were also elevated in MDA-1483, FaDu and HEp-2 cell lines when compared to the transformed keratinocyte line HEK-001. Saliva HAase levels measured using the HAase test (an ELISA-like assay) were 3.7-fold elevated in HNSCC patients (10.4 +/- 1.4 mU/mg protein) when compared to normal controls (2.8 +/- 0.7 mU/mg protein; p = 0.0028). MDA-1483 and HEp-2 cells secreted 7- to 11-fold higher levels of HAase in their conditioned media (CM) when compared to FaDu cells, and the latter secreted 1.5-fold more HAase than HEK-001 cells. Reverse transcriptase (RT)-PCR analysis detected the expression of full-length HYAL1 type HAase transcript in tumor cells. None of the cells exhibited the expression of PH20 in RT-PCR analysis. Immunoblot analysis confirmed the expression of a approximately 55 kDa HYAL-related protein in tumor cell CM and in patients' saliva. The pH activity profile and optimum (pH 4.4) of the HAase activity present in HNSCC patients' or normal saliva and that secreted in the CM of tumor cells closely resembled that of the partially purified HYAL1 type HAase. The profiles of HA species in HNSCC patients' and normal saliva are different. The high-stage HNSCC patients' saliva contains a high-molecular-mass HA species and HA fragments, in addition to the HA species present in the normal individual's saliva. These results show that HYAL1 is the major tumor-derived HAase expressed in HNSCC. Furthermore, HA and HAase may be sensitive and specific markers for detecting HNSCC and monitoring its recurrence. Further studies are needed to confirm these preliminary studies.

摘要

头颈部鳞状细胞癌(HNSCC)的特征性行为包括倾向于以多个同步和异时肿瘤的形式出现、频繁复发和转移。早期检测HNSCC并监测其复发对于改善预后至关重要。透明质酸(HA)是细胞外基质的一种成分,可促进转移。HA的小片段刺激血管生成。当内切糖苷酶透明质酸酶(HAase)降解HA聚合物时会产生HA片段。使用HA检测(一种类似ELISA的检测方法),我们发现11例HNSCC患者的唾液HA水平(2841±887 ng/mg蛋白质)比6例正常对照(579.3±122.6 ng/mg蛋白质;p = 0.00238)高4.9倍。纳入我们研究的HNSCC患者包括口腔癌(n = 4)、咽癌(n = 7)和喉癌(n = 1)患者。与转化的角质形成细胞系HEK - 001相比,MDA - 1483、FaDu和HEp - 2细胞系中的HA水平也升高。使用HAase检测(一种类似ELISA的检测方法)测量,HNSCC患者的唾液HAase水平(10.4±1.4 mU/mg蛋白质)比正常对照(2.8±0.7 mU/mg蛋白质;p = 0.0028)高3.7倍。与FaDu细胞相比,MDA - 1483和HEp - 2细胞在其条件培养基(CM)中分泌的HAase水平高7至11倍,而后者分泌的HAase比HEK - 001细胞多1.5倍。逆转录酶(RT)-PCR分析检测到肿瘤细胞中全长HYAL1型HAase转录本的表达。在RT - PCR分析中,没有细胞表现出PH20的表达。免疫印迹分析证实肿瘤细胞CM和患者唾液中存在一种约55 kDa的HYAL相关蛋白。HNSCC患者或正常唾液中存在的以及肿瘤细胞CM中分泌的HAase活性的pH活性曲线和最佳值(pH 4.4)与部分纯化的HYAL1型HAase非常相似。HNSCC患者和正常唾液中的HA种类不同。高分期HNSCC患者的唾液除了含有正常个体唾液中存在的HA种类外,还含有高分子量的HA种类和HA片段。这些结果表明HYAL1是HNSCC中主要的肿瘤来源HAase。此外,HA和HAase可能是检测HNSCC及其复发的敏感和特异性标志物。需要进一步研究来证实这些初步研究。

相似文献

1
Expression of tumor markers hyaluronic acid and hyaluronidase (HYAL1) in head and neck tumors.肿瘤标志物透明质酸和透明质酸酶(HYAL1)在头颈部肿瘤中的表达。
Int J Cancer. 2003 Sep 1;106(3):438-45. doi: 10.1002/ijc.11252.
2
Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer.肿瘤标志物透明质酸和透明质酸酶1在前列腺癌中的基质和上皮表达
J Biol Chem. 2001 Apr 13;276(15):11922-32. doi: 10.1074/jbc.M008432200. Epub 2001 Jan 19.
3
HYAL1 overexpression is correlated with the malignant behavior of human breast cancer.透明质酸酶 1 过表达与人乳腺癌的恶性行为相关。
Int J Cancer. 2011 Mar 15;128(6):1303-15. doi: 10.1002/ijc.25460.
4
Elevated tissue expression of hyaluronic acid and hyaluronidase validates the HA-HAase urine test for bladder cancer.透明质酸和透明质酸酶的组织表达升高验证了用于膀胱癌的HA-HAase尿液检测。
J Urol. 2001 Jun;165(6 Pt 1):2068-74. doi: 10.1097/00005392-200106000-00072.
5
Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer.透明质酸、透明质酸酶(HYAL-1)、CD44v6和微血管密度对前列腺癌的预后潜力比较。
Int J Cancer. 2004 Oct 20;112(1):121-9. doi: 10.1002/ijc.20368.
6
Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade.尿透明质酸和透明质酸酶:膀胱癌检测及分级评估的标志物。
J Urol. 2000 Jan;163(1):348-56. doi: 10.1016/s0022-5347(05)68050-0.
7
Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL1) for prostate cancer.评估透明质酸和透明质酸酶(HYAL1)对前列腺癌的预后潜力。
Cancer Res. 2003 May 15;63(10):2638-44.
8
Identification of bladder tumor-derived hyaluronidase: its similarity to HYAL1.膀胱肿瘤源性透明质酸酶的鉴定:其与HYAL1的相似性。
Cancer Res. 1999 Sep 1;59(17):4464-70.
9
Salivary soluble CD44: a potential molecular marker for head and neck cancer.唾液可溶性CD44:头颈部癌的潜在分子标志物。
Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):735-9. doi: 10.1158/1055-9965.EPI-04-0546.
10
Expression and activity of hyaluronidase in human periodontal ligament fibroblasts.透明质酸酶在人牙周膜成纤维细胞中的表达及活性
J Periodontol. 2002 Nov;73(11):1331-7. doi: 10.1902/jop.2002.73.11.1331.

引用本文的文献

1
Hyaluronidase: structure, mechanism of action, diseases and therapeutic targets.透明质酸酶:结构、作用机制、疾病及治疗靶点
Mol Biomed. 2025 Jul 12;6(1):50. doi: 10.1186/s43556-025-00299-y.
2
Novel Molecular Signatures Selectively Predict Clinical Outcomes in Colon Cancer.新型分子特征可选择性预测结肠癌的临床结局。
Cancers (Basel). 2025 Mar 7;17(6):919. doi: 10.3390/cancers17060919.
3
A sequential dual-locked luminescent copper nanocluster probe for tumor cell imaging and killing.一种用于肿瘤细胞成像和杀伤的顺序双锁发光铜纳米团簇探针。
Mikrochim Acta. 2024 Aug 5;191(9):511. doi: 10.1007/s00604-024-06591-y.
4
Hyaluronidase-trigger nanocarriers for targeted delivery of anti-liver cancer compound.用于靶向递送抗肝癌化合物的透明质酸酶触发纳米载体。
RSC Adv. 2023 Apr 11;13(16):11160-11170. doi: 10.1039/d3ra00693j. eCollection 2023 Apr 3.
5
Role of Hyaluronic Acid in Selected Malignant Neoplasms in Women.透明质酸在女性特定恶性肿瘤中的作用
Biomedicines. 2023 Jan 21;11(2):304. doi: 10.3390/biomedicines11020304.
6
Enzyme and Reactive Oxygen Species-Responsive Dual-Drug Delivery Nanocomplex for Tumor Chemo-Photodynamic Therapy.酶和活性氧响应型双药物递送纳米复合物用于肿瘤化学-光动力治疗。
Int J Nanomedicine. 2023 Jan 4;18:1-16. doi: 10.2147/IJN.S393862. eCollection 2023.
7
Hyaluronic Acid as a Modern Approach in Anticancer Therapy-Review.透明质酸作为一种癌症治疗的现代方法-综述。
Int J Mol Sci. 2022 Dec 21;24(1):103. doi: 10.3390/ijms24010103.
8
Theranostic Applications of Glycosaminoglycans in Metastatic Renal Cell Carcinoma.糖胺聚糖在转移性肾细胞癌中的诊疗应用
Cancers (Basel). 2022 Dec 30;15(1):266. doi: 10.3390/cancers15010266.
9
Dual-stimuli responsive smart nanoprobe for precise diagnosis and synergistic multi-modalities therapy of superficial squamous cell carcinoma.用于浅表鳞状细胞癌精准诊断和协同多模态治疗的双重刺激响应型智能纳米探针。
J Nanobiotechnology. 2023 Jan 3;21(1):4. doi: 10.1186/s12951-022-01759-1.
10
Targeted Depletion of Hyaluronic Acid Mitigates Murine Breast Cancer Growth.靶向消耗透明质酸可减轻小鼠乳腺癌生长。
Cancers (Basel). 2022 Sep 23;14(19):4614. doi: 10.3390/cancers14194614.